Number of participants with exacerbations requiring systemic steroids · patients with chronic asthma
LABA + ICS leads to lower participants with one or more exacerbations requiring systemic… compared with LTRA + ICS (high certainty).
1 finding from 1 review
Change from baseline in morning PEFR (L/min) Duration of trials: 8 to 13 weeks · patients with chronic asthma
1 finding from 1 review
Lung function: FEV1 mL (change from baseline) · patients with chronic asthma
1 finding from 1 review
Rescue‐free days: % change from baseline · patients with chronic asthma
1 finding from 1 review
Use of rescue medication · patients with chronic asthma
1 finding from 1 review
Withdrawals due to any reason · patients with chronic asthma
LABA + ICS probably leads to lower withdrawals for any reason compared with LTRA + ICS (moderate certainty).
1 finding from 1 review
Serious adverse events · patients with chronic asthma
LABA + ICS showed no clear difference in serious adverse events compared with LTRA + ICS (moderate certainty).
1 finding from 1 review
Intervention not reported
Days of catheter patency · Children with central venous catheter
1 finding from 1 review
Intervention not reported
Catheter‐related thrombosis at any time during catheter stay · Children with central venous catheter
The intervention showed no clear difference in catheter‐related thrombosis at any time during catheter stay (moderate certainty).
1 finding from 1 review
Intervention not reported
Occlusion of catheter within one week of catheter insertion · Children with central venous catheter
The intervention showed no clear difference in occlusion of catheter within one week of catheter insertion (low certainty).
1 finding from 1 review
Intervention not reported
Catheter‐related blood stream infection and CVC‐related colonization · Children with central venous catheter
The intervention may leads to lower catheter‐related blood stream infection and CVC‐related colonization (low certainty).
1 finding from 1 review
Intervention not reported
Side effects: Thrombocytopenia after catheter insertion · Children with central venous catheter
The intervention showed no clear difference in side effects: Thrombocytopenia after catheter insertion (low certainty).
1 finding from 1 review
Intervention not reported
SGRQ Scores range from 0 to 100, with higher scores indicating more limitations · 18 to 80 years of age with bronchiectasis
The intervention showed no clear difference in SGRQ Scores range from 0 to 100, with higher scores indicating more… (low certainty).
1 finding from 1 review
Intervention not reported
TDI Total scores range from ‐ 9 to +9. The lower the score, the greater the deterioration in severity of dyspnoea, MCID ≥ 1 · 18 to 80 years of age with bronchiectasis
The intervention may leads to higher TDI Total scores range from ‐ 9 to +9. The lower the score, the… (low certainty).
1 finding from 1 review
Intervention not reported
Cough‐free days Percentage of days free of cough · 18 to 80 years of age with bronchiectasis
The intervention may leads to higher cough‐free days Percentage of days free of cough (low certainty).
1 finding from 1 review
Intervention not reported
Hospitalisations, number of participants with 1 or more exacerbations · 18 to 80 years of age with bronchiectasis
The intervention showed no clear difference in hospitalisations, number of participants with 1 or more exacerbations (low certainty).
1 finding from 1 review
Number of participants with worsening scores in corporal atrophy · people with pre‐malignant lesions
Proton pump inhibitor showed no clear difference in number of participants with worsening scores in corporal atrophy compared with control (low certainty).
1 finding from 1 review
Number of participants with worsening scores in corporal intestinal metaplasia · people with pre‐malignant lesions
Proton pump inhibitor showed no clear difference in number of participants with worsening scores in corporal intestinal… compared with control (low certainty).
1 finding from 1 review
Increase in the number of participants with simple (diffuse) hyperplasia after treatment · people with pre‐malignant lesions
It is very uncertain whether proton pump inhibitor changes increase in the number of participants with simple (diffuse)… compared with control (very low certainty).
1 finding from 1 review
Increase in the number of participants with linear/micronodular (focal) hyperplasia, comparing final biopsies with baseline biopsies · people with pre‐malignant lesions
Proton pump inhibitor may leads to higher increase in the number of participants with linear/micronodular… compared with control (low certainty).
1 finding from 1 review